Piper Sandler Raises AbbVie Price Target: Strong IBD Drug Pipeline

Piper Sandler analysts have raised the price target for AbbVie (ABBV), citing strong progress in the company's drug development efforts for inflammatory bowel disease (IBD). The analysts noted that the potential of AbbVie's IBD portfolio positively impacts the company's growth expectations. The increased price target reflects confidence in AbbVie's existing drugs as well as the success of new treatments under development. In particular, clinical trial results in the IBD area are described as promising, which could enhance the company's market share. Piper Sandler's assessment is based on AbbVie's robust R&D pipeline and the sales performance of its current products. Analysts anticipate that innovations in IBD treatments could contribute significant revenue over the long term. This development is seen as a positive signal for AbbVie shares. However, investors should consider market conditions and potential risks facing the company. This is not investment advice.